Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

ConclusionVeliparib, paclitaxel, and carboplatin were well tolerated and demonstrated promising antitumor activity.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research